Loading...

Sesen Bio

DB:PCBK
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PCBK
DB
$91M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
  • Sesen Bio has significant price volatility in the past 3 months.
PCBK Share Price and Events
7 Day Returns
18.1%
DB:PCBK
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-14%
DB:PCBK
-9.2%
DE Biotechs
-6.7%
DE Market
PCBK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sesen Bio (PCBK) 18.1% 23.7% 72.4% -14% - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • PCBK underperformed the Biotechs industry which returned -9.2% over the past year.
  • PCBK underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
PCBK
Industry
5yr Volatility vs Market
Related Companies

PCBK Value

 Is Sesen Bio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Sesen Bio to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Sesen Bio.

DB:PCBK Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:PCBK
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (0%))
1.306
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.306 * 5.96%)
8.01%

Discounted Cash Flow Calculation for DB:PCBK using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Sesen Bio is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:PCBK DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.01%)
2019 -36.82 Analyst x2 -34.09
2020 -39.15 Analyst x2 -33.56
2021 -41.20 Analyst x2 -32.70
2022 -0.83 Analyst x2 -0.61
2023 41.72 Analyst x2 28.38
2024 68.67 Est @ 64.58% 43.25
2025 99.76 Est @ 45.28% 58.17
2026 131.44 Est @ 31.76% 70.97
2027 160.75 Est @ 22.3% 80.36
2028 185.96 Est @ 15.68% 86.06
Present value of next 10 years cash flows $266.24
DB:PCBK DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $185.96 × (1 + 0.23%) ÷ (8.01% – 0.23%)
$2,395.39
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,395.39 ÷ (1 + 8.01%)10
$1,108.61
DB:PCBK Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $266.24 + $1,108.61
$1,374.85
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,374.85 / 77.46
$17.75
DB:PCBK Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:PCBK represents 0.8678x of NasdaqGM:SESN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8678x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 17.75 x 0.8678
€15.40
Value per share (EUR) From above. €15.40
Current discount Discount to share price of €1.02
= -1 x (€1.02 - €15.40) / €15.40
93.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Sesen Bio is available for.
Intrinsic value
>50%
Share price is €1.02 vs Future cash flow value of €15.4
Current Discount Checks
For Sesen Bio to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Sesen Bio's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Sesen Bio's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sesen Bio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sesen Bio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PCBK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.55
NasdaqGM:SESN Share Price ** NasdaqGM (2019-04-18) in USD $1.18
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sesen Bio.

DB:PCBK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:SESN Share Price ÷ EPS (both in USD)

= 1.18 ÷ -0.55

-2.16x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sesen Bio is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Sesen Bio is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Sesen Bio's expected growth come at a high price?
Raw Data
DB:PCBK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.16x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
27.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sesen Bio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sesen Bio's assets?
Raw Data
DB:PCBK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.57
NasdaqGM:SESN Share Price * NasdaqGM (2019-04-18) in USD $1.18
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:PCBK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:SESN Share Price ÷ Book Value per Share (both in USD)

= 1.18 ÷ 0.57

2.07x

* Primary Listing of Sesen Bio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sesen Bio is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Sesen Bio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sesen Bio has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PCBK Future Performance

 How is Sesen Bio expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
27.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sesen Bio expected to grow at an attractive rate?
  • Sesen Bio's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Sesen Bio's earnings growth is expected to exceed the Germany market average.
  • Sesen Bio's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:PCBK Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PCBK Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 27.8%
DB:PCBK Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 73.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PCBK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PCBK Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 108 40 42 4
2022-12-31 61 -2 -14 4
2021-12-31 20 -40 -43 4
2020-12-31 3 -37 -41 4
2019-12-31 0 -37 -34 4
DB:PCBK Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -23 -34
2018-09-30 0 -19 -33
2018-06-30 0 -18 -29
2018-03-31 0 -17 -27
2017-12-31 0 -18 -29
2017-09-30 1 -20 -26
2017-06-30 30 6 3
2017-03-31 30 6 3
2016-12-31 30 3 2
2016-09-30 30 -1 -5
2016-06-30 1 -31 -34
2016-03-31 1 -35 -35

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sesen Bio's earnings are expected to grow significantly at over 20% yearly.
  • Sesen Bio's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PCBK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Sesen Bio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PCBK Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.35 0.36 0.34 2.00
2022-12-31 -0.11 0.02 -0.27 4.00
2021-12-31 -0.44 -0.24 -0.62 4.00
2020-12-31 -0.44 -0.38 -0.54 4.00
2019-12-31 -0.42 -0.30 -0.58 4.00
DB:PCBK Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.55
2018-09-30 -0.67
2018-06-30 -0.78
2018-03-31 -0.93
2017-12-31 -1.11
2017-09-30 -1.06
2017-06-30 0.11
2017-03-31 0.15
2016-12-31 0.09
2016-09-30 -0.25
2016-06-30 -1.74
2016-03-31 -1.78

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sesen Bio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Sesen Bio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sesen Bio has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PCBK Past Performance

  How has Sesen Bio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sesen Bio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sesen Bio does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Sesen Bio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sesen Bio's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Sesen Bio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sesen Bio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PCBK Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -33.69 11.62
2018-09-30 0.00 -33.48 10.11
2018-06-30 0.00 -28.57 7.92
2018-03-31 0.00 -26.93 7.81
2017-12-31 0.43 -29.03 8.07
2017-09-30 1.25 -26.01 5.54
2017-06-30 29.90 2.58 10.27
2017-03-31 30.18 3.40 11.50
2016-12-31 29.98 1.89 11.44
2016-09-30 29.72 -4.91 14.30
2016-06-30 1.14 -34.09 10.62
2016-03-31 0.98 -34.50 9.39
2015-12-31 0.99 -33.45 9.85
2015-09-30 0.80 -31.26 9.74
2015-06-30 1.27 -32.24 9.33
2015-03-31 1.92 -33.46 9.14
2014-12-31 2.24 -34.68 8.47
2014-09-30 2.38 -32.74 7.66
2014-06-30 2.46 -26.79 6.18
2014-03-31 1.90 -23.22 5.01
2013-12-31 1.33 -21.88 4.02
2013-09-30 0.82 -21.68 3.74 15.26
2013-06-30 0.20 -22.70 3.88 15.26
2013-03-31 -23.66 4.08 15.26
2012-12-31 -22.77 4.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sesen Bio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sesen Bio has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sesen Bio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sesen Bio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sesen Bio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PCBK Health

 How is Sesen Bio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sesen Bio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sesen Bio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sesen Bio's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Sesen Bio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Sesen Bio has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sesen Bio Company Filings, last reported 3 months ago.

DB:PCBK Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 44.21 0.00 50.42
2018-09-30 50.40 0.00 57.86
2018-06-30 64.06 0.00 62.96
2018-03-31 23.86 0.00 19.69
2017-12-31 18.03 0.00 14.68
2017-09-30 17.07 0.00 11.34
2017-06-30 25.91 0.00 15.75
2017-03-31 32.91 0.00 20.27
2016-12-31 38.68 0.00 25.34
2016-09-30 41.45 0.00 30.72
2016-06-30 6.17 0.00 8.48
2016-03-31 11.97 0.00 13.42
2015-12-31 18.94 13.90 36.08
2015-09-30 28.67 14.73 46.36
2015-06-30 37.22 14.69 53.49
2015-03-31 30.97 10.00 45.55
2014-12-31 36.83 10.00 54.06
2014-09-30 28.78 3.29 35.94
2014-06-30 38.62 3.70 45.03
2014-03-31 46.23 4.11 53.96
2013-12-31 2.35 4.52 7.94
2013-09-30 6.53 4.94 12.91
2013-06-30 -2.67 8.17 7.08
2013-03-31 5.74 2.01 7.88
2012-12-31 5.74 2.01 7.88
  • Sesen Bio has no debt.
  • Sesen Bio has no debt compared to 5 years ago when it was 159.3%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sesen Bio has sufficient cash runway for 2.2 years based on current free cash flow.
  • Sesen Bio has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of -11% each year.
X
Financial health checks
We assess Sesen Bio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sesen Bio has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PCBK Dividends

 What is Sesen Bio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sesen Bio dividends.
If you bought €2,000 of Sesen Bio shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sesen Bio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sesen Bio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PCBK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PCBK Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sesen Bio has not reported any payouts.
  • Unable to verify if Sesen Bio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sesen Bio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sesen Bio has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sesen Bio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sesen Bio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sesen Bio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PCBK Management

 What is the CEO of Sesen Bio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Thomas Cannell
AGE 56
TENURE AS CEO 0.7 years
CEO Bio

Dr. Thomas R. Cannell, DVM, is President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June 8, 2016 and Executive Vice President since July 2015 until July 27, 2018. Dr. Cannell served as President of Global Commercial Products at Orexigen Therapeutics, Inc. since June 8, 2016 until July 27, 2018. He served as the Chief Commercial Officer of Orexigen Therapeutics, Inc. from March 2015 to June 8, 2016. Dr. Cannell served as the President and Managing Director at Merck Canada Inc. (formerly, Merck Frosst Canada Ltd.) since January 1, 2013. He joined to Merck Europe/Canada region from Japan, where in 2010 he joined the Japanese organization as Vice President and Executive Officer, Head of Marketing and Chief Strategy Officer. In this position, he played an instrumental role in the development of the Japanese 10-Year Strategic Plan, while leading business innovation and other key strategic initiatives. While in Japan, he oversaw the product launches of Gardasil ® , Cubicin ® , Cancidas ® and Rotateq ®. He served as the Head of Marketing and Strategy for MSD Japan. He began his career with Merck Frosst Canada in 1987 as a Sales Representative and over the course of his career has held positions of increasing responsibility in strategic planning, marketing and sales. Dr. Cannell has demonstrated leadership in developing and implementing business plans designed to support Merck's strategic growth initiatives in the United States and abroad. In 2007, as the General Manager for the New Commercial Model, he led the team responsible for designing and testing the business model. He is a Member of Canada's Research-Based Pharmaceutical Companies (Rx&D) Board of Directors. He has also served in the U.S. Army Reserves (currently inactive) since 1987. Dr. Cannell received his BS and Doctor of Veterinary Medicine (DVM) from Washington State University and practiced as a Small Animal Veterinarian in Washington State.

CEO Compensation
  • Insufficient data for Thomas to compare compensation growth.
  • Insufficient data for Thomas to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Sesen Bio management team in years:

1.1
Average Tenure
57.5
Average Age
  • The average tenure for the Sesen Bio management team is less than 2 years, this suggests a new team.
Management Team

Rich Fitzgerald

TITLE
CFO, Secretary & Treasurer
COMPENSATION
$68K
AGE
54
TENURE
1.5 yrs

Thomas Cannell

TITLE
President
AGE
56
TENURE
0.7 yrs

Chris Garcia

TITLE
Co-Founder & Member of Scientific Advisory Board

Greg Verdine

TITLE
Co-Founder
AGE
59

Casey Weaver

TITLE
Co-Founder & Member of Scientific Advisory Board

Glen MacDonald

TITLE
Chief Technology Officer
AGE
67

Greg Adams

TITLE
Chief Scientific Officer
AGE
59

Erin Clark

TITLE
Executive Director

David Brooks

TITLE
Senior Vice President of Clinical Development
TENURE
1.9 yrs

Dennis Kim

TITLE
Chief Medical Officer
AGE
50
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Sesen Bio board of directors in years:

4.3
Average Tenure
59.5
Average Age
  • The tenure for the Sesen Bio board of directors is about average.
Board of Directors

Wendy Dixon

TITLE
Chairman
COMPENSATION
$107K
AGE
63
TENURE
2.3 yrs

Thomas Cannell

TITLE
President
AGE
56
TENURE
0.7 yrs

Chris Garcia

TITLE
Co-Founder & Member of Scientific Advisory Board

Casey Weaver

TITLE
Co-Founder & Member of Scientific Advisory Board

Jane Pritchett Henderson

TITLE
Director
COMPENSATION
$62K
AGE
52
TENURE
5.2 yrs

Reza Dana

TITLE
Member of Scientific Advisory Board

Dan Lynch

TITLE
Director
COMPENSATION
$64K
AGE
60
TENURE
5.2 yrs

Barry Gertz

TITLE
Director
COMPENSATION
$43K
AGE
66
TENURE
4.3 yrs

Jay Duker

TITLE
Director
COMPENSATION
$43K
AGE
59
TENURE
4.3 yrs

Peter Campochiaro

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Sesen Bio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sesen Bio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PCBK News

Simply Wall St News

PCBK Company Info

Description

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The company’s lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate, which is in Phase I/II clinical trials for use in the treatment of various types of EpCAM-positive solid tumors. It is also developing Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca’s checkpoint inhibitor that is in Phase I/IIa clinical trials for the treatment of squamous cell carcinoma of the head and neck. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Details
Name: Sesen Bio, Inc.
PCBK
Exchange: DB
Founded: 2008
$81,307,921
77,456,180
Website: http://www.sesenbio.com
Address: Sesen Bio, Inc.
245 First Street,
Suite 1800,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM SESN Common Stock Nasdaq Global Market US USD 06. Feb 2014
DB PCBK Common Stock Deutsche Boerse AG DE EUR 06. Feb 2014
Number of employees
Current staff
Staff numbers
24
Sesen Bio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:24
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.